Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Tuberculosis among asylum-seekers in Milan, Italy: Epidemiological analysis and evaluation of interventions.

Villa S, Codecasa LR, Faccini M, Pontello MM, Ferrarese M, Castellotti PF, Senatore S, Lamberti A, Mazzola E, Perno CF, Campisi D, Saporiti M, Raviglione MC.

Eur Respir J. 2019 Aug 14. pii: 1900896. doi: 10.1183/13993003.00896-2019. [Epub ahead of print]

PMID:
31413161
2.

Precision medicine and public health interventions: tuberculosis as a model?

Temesgen Z, Cirillo DM, Raviglione MC.

Lancet Public Health. 2019 Aug;4(8):e374. doi: 10.1016/S2468-2667(19)30130-6. No abstract available.

3.

Migrants' health: Building migrant-sensitive health systems.

Villa S, Raviglione MC.

J Public Health Res. 2019 May 3;8(1):1592. doi: 10.4081/jphr.2019.1592. eCollection 2019 Mar 11. No abstract available.

4.

Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives.

Pontali E, Raviglione MC, Migliori GB; and the writing group members of the Global TB Network Clinical Trials Committee.

Eur Respir Rev. 2019 May 29;28(152). pii: 190035. doi: 10.1183/16000617.0035-2019. Print 2019 Jun 30.

5.

Building a tuberculosis-free world: The Lancet Commission on tuberculosis.

Reid MJA, Arinaminpathy N, Bloom A, Bloom BR, Boehme C, Chaisson R, Chin DP, Churchyard G, Cox H, Ditiu L, Dybul M, Farrar J, Fauci AS, Fekadu E, Fujiwara PI, Hallett TB, Hanson CL, Harrington M, Herbert N, Hopewell PC, Ikeda C, Jamison DT, Khan AJ, Koek I, Krishnan N, Motsoaledi A, Pai M, Raviglione MC, Sharman A, Small PM, Swaminathan S, Temesgen Z, Vassall A, Venkatesan N, van Weezenbeek K, Yamey G, Agins BD, Alexandru S, Andrews JR, Beyeler N, Bivol S, Brigden G, Cattamanchi A, Cazabon D, Crudu V, Daftary A, Dewan P, Doepel LK, Eisinger RW, Fan V, Fewer S, Furin J, Goldhaber-Fiebert JD, Gomez GB, Graham SM, Gupta D, Kamene M, Khaparde S, Mailu EW, Masini EO, McHugh L, Mitchell E, Moon S, Osberg M, Pande T, Prince L, Rade K, Rao R, Remme M, Seddon JA, Selwyn C, Shete P, Sachdeva KS, Stallworthy G, Vesga JF, Vilc V, Goosby EP.

Lancet. 2019 Mar 30;393(10178):1331-1384. doi: 10.1016/S0140-6736(19)30024-8. Epub 2019 Mar 20. Review. No abstract available.

PMID:
30904263
6.

Global Epidemiology of Tuberculosis.

Glaziou P, Floyd K, Raviglione MC.

Semin Respir Crit Care Med. 2018 Jun;39(3):271-285. doi: 10.1055/s-0038-1651492. Epub 2018 Aug 2. Review.

PMID:
30071543
7.

Ending tuberculosis in India: A political challenge & an opportunity.

Dias HMY, Pai M, Raviglione MC.

Indian J Med Res. 2018 Mar;147(3):217-220. doi: 10.4103/ijmr.IJMR_660_18. No abstract available.

8.

Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study.

Zignol M, Cabibbe AM, Dean AS, Glaziou P, Alikhanova N, Ama C, Andres S, Barbova A, Borbe-Reyes A, Chin DP, Cirillo DM, Colvin C, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Hussain A, Ismail N, Kamal SMM, Khanzada FM, Kimerling M, Kohl TA, Mansjö M, Miotto P, Mukadi YD, Mvusi L, Niemann S, Omar SV, Rigouts L, Schito M, Sela I, Seyfaddinova M, Skenders G, Skrahina A, Tahseen S, Wells WA, Zhurilo A, Weyer K, Floyd K, Raviglione MC.

Lancet Infect Dis. 2018 Jun;18(6):675-683. doi: 10.1016/S1473-3099(18)30073-2. Epub 2018 Mar 21. Erratum in: Lancet Infect Dis. 2018 Mar 27;:.

9.

The World Health Organization standards for tuberculosis care and management.

Gilpin C, Korobitsyn A, Migliori GB, Raviglione MC, Weyer K.

Eur Respir J. 2018 Mar 22;51(3). pii: 1800098. doi: 10.1183/13993003.00098-2018. Print 2018 Mar. No abstract available.

10.

A New World Health Era.

Pablos-Méndez A, Raviglione MC.

Glob Health Sci Pract. 2018 Mar 30;6(1):8-16. doi: 10.9745/GHSP-D-17-00297. Print 2018 Mar 21. No abstract available.

11.

Migrant health and tuberculosis.

Raviglione MC, Mosca D.

Int J Tuberc Lung Dis. 2017 Jun 1;21(6):599-600. doi: 10.5588/ijtld.17.0209. No abstract available.

PMID:
28482951
12.

Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance.

Zignol M, Dean AS, Falzon D, van Gemert W, Wright A, van Deun A, Portaels F, Laszlo A, Espinal MA, Pablos-Méndez A, Bloom A, Aziz MA, Weyer K, Jaramillo E, Nunn P, Floyd K, Raviglione MC.

N Engl J Med. 2016 Sep 15;375(11):1081-9. doi: 10.1056/NEJMsr1512438. No abstract available.

13.

Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.

Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Husain A, Hussain A, Ismail N, Kamal M, Mansjö M, Mvusi L, Niemann S, Omar SV, Qadeer E, Rigouts L, Ruesch-Gerdes S, Schito M, Seyfaddinova M, Skrahina A, Tahseen S, Wells WA, Mukadi YD, Kimerling M, Floyd K, Weyer K, Raviglione MC.

Lancet Infect Dis. 2016 Oct;16(10):1185-1192. doi: 10.1016/S1473-3099(16)30190-6. Epub 2016 Jul 7.

14.

Digital health for the End TB Strategy: developing priority products and making them work.

Falzon D, Timimi H, Kurosinski P, Migliori GB, Van Gemert W, Denkinger C, Isaacs C, Story A, Garfein RS, do Valle Bastos LG, Yassin MA, Rusovich V, Skrahina A, Van Hoi L, Broger T, Abubakar I, Hayward A, Thomas BV, Temesgen Z, Quraishi S, von Delft D, Jaramillo E, Weyer K, Raviglione MC.

Eur Respir J. 2016 Jul;48(1):29-45. doi: 10.1183/13993003.00424-2016. Epub 2016 May 26.

15.

Cameroon's multidrug-resistant tuberculosis treatment programme jeopardised by cross-border migration.

Matteelli A, Lönnroth K, Mosca D, Getahun H, Centis R, D'Ambrosio L, Jaramillo E, Migliori GB, Raviglione MC.

Eur Respir J. 2016 Feb;47(2):686-8. doi: 10.1183/13993003.01597-2015. No abstract available.

16.

Towards tuberculosis elimination: an action framework for low-incidence countries.

Lönnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, Douglas P, Falzon D, Gaudreau MA, Goletti D, González Ochoa ER, LoBue P, Matteelli A, Njoo H, Solovic I, Story A, Tayeb T, van der Werf MJ, Weil D, Zellweger JP, Abdel Aziz M, Al Lawati MR, Aliberti S, Arrazola de Oñate W, Barreira D, Bhatia V, Blasi F, Bloom A, Bruchfeld J, Castelli F, Centis R, Chemtob D, Cirillo DM, Colorado A, Dadu A, Dahle UR, De Paoli L, Dias HM, Duarte R, Fattorini L, Gaga M, Getahun H, Glaziou P, Goguadze L, Del Granado M, Haas W, Järvinen A, Kwon GY, Mosca D, Nahid P, Nishikiori N, Noguer I, O'Donnell J, Pace-Asciak A, Pompa MG, Popescu GG, Robalo Cordeiro C, Rønning K, Ruhwald M, Sculier JP, Simunović A, Smith-Palmer A, Sotgiu G, Sulis G, Torres-Duque CA, Umeki K, Uplekar M, van Weezenbeek C, Vasankari T, Vitillo RJ, Voniatis C, Wanlin M, Raviglione MC.

Eur Respir J. 2015 Apr;45(4):928-52. doi: 10.1183/09031936.00214014. Review.

17.

Ensuring rational introduction and responsible use of new TB tools: outcome of an ERS multisector consultation.

Migliori GB, Lienhardt C, Weyer K, van der Werf MJ, Blasi F, Raviglione MC.

Eur Respir J. 2014 Dec;44(6):1412-7. doi: 10.1183/09031936.00132114. No abstract available.

18.

Tuberculosis: epidemiology and control.

Sulis G, Roggi A, Matteelli A, Raviglione MC.

Mediterr J Hematol Infect Dis. 2014 Nov 1;6(1):e2014070. doi: 10.4084/MJHID.2014.070. eCollection 2014. Review.

19.

Rapid impact of effective chemotherapy on transmission of drug-resistant tuberculosis: pity the guinea pig.

Farmer PE, Raviglione MC.

Int J Tuberc Lung Dis. 2014 Sep;18(9):1009-11. doi: 10.5588/ijtld.14.0538. No abstract available.

PMID:
25189545
20.

Tuberculosis elimination: dream or reality? The case of Cyprus.

Voniatis C, Migliori GB, Voniatis M, Georgiou A, D'Ambrosio L, Centis R, Raviglione MC.

Eur Respir J. 2014 Aug;44(2):543-6. doi: 10.1183/09031936.00044314. Epub 2014 Apr 17. No abstract available.

21.

Drug-resistant tuberculosis: latest advances.

Falzon D, Weyer K, Raviglione MC.

Lancet Respir Med. 2013 Mar;1(1):e9-e10. doi: 10.1016/S2213-2600(12)70056-5. Epub 2013 Jan 14. No abstract available.

PMID:
24321818
22.

Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data.

Falzon D, Jaramillo E, Wares F, Zignol M, Floyd K, Raviglione MC.

Lancet Infect Dis. 2013 Aug;13(8):690-7. doi: 10.1016/S1473-3099(13)70130-0. Epub 2013 Jun 4.

PMID:
23743044
23.

Isoniazid preventive treatment: predictors of adverse events and treatment completion.

Codecasa LR, Murgia N, Ferrarese M, Delmastro M, Repossi AC, Casali L, Besozzi G, Ferrara G, Raviglione MC.

Int J Tuberc Lung Dis. 2013 Jul;17(7):903-8. doi: 10.5588/ijtld.12.0677. Epub 2013 May 3.

PMID:
23651743
24.

Setting new targets in the fight against tuberculosis.

Raviglione MC, Ditiu L.

Nat Med. 2013 Mar;19(3):263. doi: 10.1038/nm.3129. No abstract available.

PMID:
23467231
25.

Epidemiology of antituberculosis drug resistance in Saudi Arabia: findings of the first national survey.

Al-Hajoj S, Varghese B, Shoukri MM, Al-Omari R, Al-Herbwai M, Alrabiah F, Alrajhi AA, Abuljadayel N, Al-Thawadi S, Zumla A, Zignol M, Raviglione MC, Memish Z.

Antimicrob Agents Chemother. 2013 May;57(5):2161-6. doi: 10.1128/AAC.02403-12. Epub 2013 Mar 4.

26.

WHO and the future of disease control programmes.

Dye C, Mertens T, Hirnschall G, Mpanju-Shumbusho W, Newman RD, Raviglione MC, Savioli L, Nakatani H.

Lancet. 2013 Feb 2;381(9864):413-8. doi: 10.1016/S0140-6736(12)61812-1.

PMID:
23374479
27.

Hurry up and wait? Accelerating access to the Three I's for HIV-TB.

Granich R, Getahun H, Hirnschall G, Raviglione MC.

Int J Tuberc Lung Dis. 2012 Jul;16(7):853-4. doi: 10.5588/ijtld.12.0406. No abstract available.

PMID:
22687495
28.

Multidrug-resistant tuberculosis in Eastern Europe: still on the increase?

Migliori GB, Dara M, de Colombani P, Kluge H, Raviglione MC.

Eur Respir J. 2012 Jun;39(6):1290-1. doi: 10.1183/09031936.00214411. No abstract available.

29.

European union standards for tuberculosis care.

Migliori GB, Zellweger JP, Abubakar I, Ibraim E, Caminero JA, De Vries G, D'Ambrosio L, Centis R, Sotgiu G, Menegale O, Kliiman K, Aksamit T, Cirillo DM, Danilovits M, Dara M, Dheda K, Dinh-Xuan AT, Kluge H, Lange C, Leimane V, Loddenkemper R, Nicod LP, Raviglione MC, Spanevello A, Thomsen VØ, Villar M, Wanlin M, Wedzicha JA, Zumla A, Blasi F, Huitric E, Sandgren A, Manissero D.

Eur Respir J. 2012 Apr;39(4):807-19. doi: 10.1183/09031936.00203811.

30.

What research is needed to stop TB? Introducing the TB Research Movement.

Lienhardt C, Espinal M, Pai M, Maher D, Raviglione MC.

PLoS Med. 2011 Nov;8(11):e1001135. doi: 10.1371/journal.pmed.1001135. Epub 2011 Nov 29. Review. No abstract available.

31.

Towards the development of EU/EEA Standards for Tuberculosis Care (ESTC).

Migliori GB, Sotgiu G, Blasi F, Zumla A, Loddenkemper R, Raviglione MC, Abubakar I, Sandgren A, Manissero D.

Eur Respir J. 2011 Sep;38(3):493-5. doi: 10.1183/09031936.00094211. No abstract available.

32.

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.

Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH, Keravec J, Keshavjee S, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev A, Migliori GB, Mirzayev F, Mitnick CD, Nunn P, Nwagboniwe G, Oxlade O, Palmero D, Pavlinac P, Quelapio MI, Raviglione MC, Rich ML, Royce S, Rüsch-Gerdes S, Salakaia A, Sarin R, Sculier D, Varaine F, Vitoria M, Walson JL, Wares F, Weyer K, White RA, Zignol M.

Eur Respir J. 2011 Sep;38(3):516-28. doi: 10.1183/09031936.00073611. Epub 2011 Aug 4.

33.

Preventing and managing antimicrobial resistance: imperative for chest physicians.

Raviglione MC, Lange C, Migliori GB.

Eur Respir J. 2011 May;37(5):978-81. doi: 10.1183/09031936.00003111. No abstract available.

34.

Here is diabetes in The Lancet's tuberculosis series!

Lönnroth K, Raviglione MC.

Lancet. 2010 Dec 11;376(9757):1987-8. doi: 10.1016/S0140-6736(10)62262-3. No abstract available.

PMID:
21146102
35.

Tuberculosis control and elimination 2010-50: cure, care, and social development.

Lönnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, Raviglione MC.

Lancet. 2010 May 22;375(9728):1814-29. doi: 10.1016/S0140-6736(10)60483-7.

PMID:
20488524
36.

Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action.

Marais BJ, Raviglione MC, Donald PR, Harries AD, Kritski AL, Graham SM, El-Sadr WM, Harrington M, Churchyard G, Mwaba P, Sanne I, Kaufmann SH, Whitty CJ, Atun R, Zumla A.

Lancet. 2010 Jun 19;375(9732):2179-91. doi: 10.1016/S0140-6736(10)60554-5. Epub 2010 May 18. Review.

PMID:
20488521
37.

New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes.

Lienhardt C, Vernon A, Raviglione MC.

Curr Opin Pulm Med. 2010 May;16(3):186-93. doi: 10.1097/MCP.0b013e328337580c. Review.

PMID:
20216421
38.

A road map to control malaria, tuberculosis, and human immunodeficiency virus/AIDS.

Frieden TR, Teklehaimanot A, Chideya S, Farmer P, Kim JY, Raviglione MC.

Arch Intern Med. 2009 Oct 12;169(18):1650-2. doi: 10.1001/archinternmed.2009.309. No abstract available.

PMID:
19822819
39.

World Tuberculosis Day 2009: partnership for TB care.

Yesudian HM, Raviglione MC.

Indian J Med Res. 2009 Mar;129(3):215-8. No abstract available.

PMID:
19491410
40.

Informed patient consent for defaulter tracing: should we obtain it?

Ohkado A, Sugiyama T, Murakami K, Ishikawa N, Borgdorff M, van Cleeff M, Gondrie P, Trébucq A, Ngamvithayapong-Yanai J, Kantipong P, Moolphate S, Luangjina S, Weil DE, Zignol M, Raviglione MC, Enarson DA, Harries AD.

Int J Tuberc Lung Dis. 2009 May;13(5):551-5. Review.

PMID:
19383185
41.

Facing extensively drug-resistant tuberculosis--a hope and a challenge.

Raviglione MC.

N Engl J Med. 2008 Aug 7;359(6):636-8. doi: 10.1056/NEJMe0804906. No abstract available.

42.

From threat to reality: the real face of multidrug-resistant tuberculosis.

Espinal M, Raviglione MC.

Am J Respir Crit Care Med. 2008 Aug 1;178(3):216-7. doi: 10.1164/rccm.200805-788ED. No abstract available.

PMID:
18650570
43.

Extensively drug-resistant tuberculosis, Italy and Germany.

Migliori GB, Ortmann J, Girardi E, Besozzi G, Lange C, Cirillo DM, Ferrarese M, De Iaco G, Gori A, Raviglione MC; SMIRA/TBNET Study Group.

Emerg Infect Dis. 2007 May;13(5):780-2. No abstract available.

44.

Clinical and operational value of the extensively drug-resistant tuberculosis definition.

Migliori GB, Besozzi G, Girardi E, Kliiman K, Lange C, Toungoussova OS, Ferrara G, Cirillo DM, Gori A, Matteelli A, Spanevello A, Codecasa LR, Raviglione MC; SMIRA/TBNET Study Group.

Eur Respir J. 2007 Oct;30(4):623-6. Epub 2007 Aug 9.

45.

The "vertical-horizontal" debates: time for the pendulum to rest (in peace)?

Uplekar M, Raviglione MC.

Bull World Health Organ. 2007 May;85(5):413-4. No abstract available.

46.

Planning to improve global health: the next decade of tuberculosis control.

Maher D, Dye C, Floyd K, Pantoja A, Lonnroth K, Reid A, Nathanson E, Pennas T, Fruth U, Cunningham J, Ignatius H, Raviglione MC, Koek I, Espinal M.

Bull World Health Organ. 2007 May;85(5):341-7.

47.

The new Stop TB Strategy and the Global Plan to Stop TB, 2006-2015.

Raviglione MC.

Bull World Health Organ. 2007 May;85(5):327. No abstract available.

48.

125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic?

Migliori GB, Loddenkemper R, Blasi F, Raviglione MC.

Eur Respir J. 2007 Mar;29(3):423-7. No abstract available.

49.

XDR tuberculosis--implications for global public health.

Raviglione MC, Smith IM.

N Engl J Med. 2007 Feb 15;356(7):656-9. No abstract available.

50.

Patients with previously treated tuberculosis no longer neglected.

Zignol M, Wright A, Jaramillo E, Nunn P, Raviglione MC.

Clin Infect Dis. 2007 Jan 1;44(1):61-4. Epub 2006 Nov 20.

PMID:
17143816

Supplemental Content

Loading ...
Support Center